{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071551","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.058128+00:00","generated_at":"2026-05-21T08:11:08.249189+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Precision BioSciences accelerates PBGENE-DMD, plans IND/CTA in 2025; pauses PBGENE-3243","bullets":["PBGENE-DMD is a first-in-class in vivo gene editing approach targeting exons 45-55; up to 60% of DMD patients carry mutations in this hotspot region.","Preclinical data shows durable functional improvement in a humanized DMD mouse model over 9 months with restored dystrophin expression.","Precision targets to file IND/CTA for PBGENE-DMD in 2025, with clinical data expected in 2026.","Company pauses development of PBGENE-3243 (m.3243 mitochondrial disease) to prioritize PBGENE-DMD and HBV; cash runway sufficient for both through Phase 1.","PBGENE-DMD preclinical data presented at ASGCT Annual Meeting on May 14, 2025; webcast held May 15."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071551","json":"https://secwatch.observer/filing/0000950170-25-071551.json","markdown":"https://secwatch.observer/filing/0000950170-25-071551.md","text":"https://secwatch.observer/filing/0000950170-25-071551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017025071551/0000950170-25-071551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017025071551/dtil-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:11:08.249189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}